NCT06512831

Isoniazid Prophylaxis Based on Risk Factors of Tuberculosis in Living Kidney Transplantation Recipients

Isoniazid Prophylaxis Based on Risk Factors of Tuberculosis in Living Kidney Transplantation Recipients: A Retrospective Cohort Study

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 1,348 (actual)
• Sponsor: West China Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Tuberculosis (TB) is a major and severe opportunistic infection among solid organ transplant recipients. Chemoprophylaxis is advised for those with latent tuberculosis infection (LTBI). However, the effectiveness of an isoniazid (INH) prophylactic approach based on TB risk factors, without relying on tuberculin skin test (TST) or interferon-gamma release assay (IGRA), remains uncertain. Therefore, the investigators conducted this retrospective study to evaluate the safety and efficacy of a 6-month INH prophylaxis regimen guided by TB risk factors in kidney transplant recipients.

Conditions

• Kidney Transplantation
• Tuberculosis
• Isoniazid Toxicity

Interventions

Type	Name	Description
DRUG	Isoniazid	Those with risk factors were recommended a 6-month prophylaxis regimen, consisting of INH (300 mg/d) and pyridoxine (10 mg/d to prevent INH-related neurotoxicity).

Timeline

• Start date: 2023-06-01
• Primary completion: 2024-02-01
• Completion: 2024-03-01
• First posted: 2024-07-22
• Last updated: 2024-07-22

Locations

1 site across 1 country: China